Precision Medicine Capabilities


The wealth of human tumor genomic data and mechanistic understanding of drivers of disease progression has allowed for a more refined stratification of tumor subtypes and disease states enabling an opportunity to select a particular targeted therapy for a patient’s cancer. Precision medicine is used for treating cancer patients with individualized, targeted therapies based on the specific molecular profile of their tumors, with the aim of providing more effective care and improved clinical responses.

IDEAYA, with its capabilities and approach to precision medicine, strives to be a leader in this “Golden Age” of oncology drug discovery and development.  The company has a diversified approach and is developing a deep pipeline of potential therapies based on synthetic lethality, as well as direct targeting of oncogenic pathways.

Our organization was founded with the vision of establishing the leading precision medicine company with capabilities that enable an integrated approach for biomarker and small molecule drug discovery and development to broadly address unmet needs in cancer. Our capabilities include target and biomarker discovery integrated with small molecule therapeutics, from early discovery through clinical development.

Synthetic Lethality is an emerging area within precision medicine oncology, presenting an opportunity to deliver the next generation of targeted therapies for patients. Advancements in molecular biology research, including genetic knockdown and editing capabilities, are enabling the identification and validation of novel biological targets. Programs in Synthetic Lethality represent exciting opportunities with the potential to be broadly impactful for patients.

William R. Sellers, M.D.IDEAYA Scientific Advisory Board